Home Blog Page 426

2026 Ningbo Image Overseas Exhibition Concludes Successfully in Hong Kong, China


HONG KONG SAR – Media OutReach Newswire – 26 March 2026 – On the afternoon of 21 March, the 2026 Ningbo Image Overseas Exhibition took place at the Hong Kong CineArt MegaBox. Using visual media as a connecting thread, the event built a bridge for cultural exchange between Ningbo and Hong Kong, allowing Hong Kong audiences to experience the charm of Ningbo up close.

2026 Ningbo Image Overseas Exhibition Concludes Successfully in HongKong, China

The event comprised three components: a Ningbo-themed film screening, a creative salon, and the ‘Experience Ningbo’ city exhibition, attracting enthusiastic participation from staff and students of Hong Kong Baptist University, as well as local cultural figures.

The Ningbo-themed film screening presented three films from Ningbo and five short films from the 30°Ningbo Short Film Festival, showcasing Ningbo’s cultural heritage and natural scenery through the lens.

The creative salon invited three guests—director Jiang Xiaoxuan, Hong Kong Baptist University lecturer Lai Kin-fung, and Southern Film Company Limited‌ Manager Lin Yunhua—to explore new avenues for the visual dissemination of local culture from the perspectives of film and television production and the cultural fusion between the two regions.

The “Experience Ningbo” exhibition, through the promotion of local cuisine and scenic beauty alongside displays of urban cultural and creative products, allowed audiences to experience Ningbo through both sight and taste. Many visitors expressed their desire to visit Ningbo in person.

This event created a “visible, tangible and portable” record of the city’s culture, further deepening cultural exchanges between Ningbo and Hong Kong. Moving forward, the film exhibition will tour more overseas cities, using the medium of film to promote Ningbo to the world.

Hashtag: #2026NingboImageOverseasExhibition

The issuer is solely responsible for the content of this announcement.

Wellcome and COFCO Hong Kong Announce Strategic Partnership Target First-Year Sales to Exceed HK$100 Million

Stabilising the Supply of Quality Food and Strengthening Price Competitiveness


HONG KONG SAR – Media OutReach Newswire – 26 March 2026 – Wellcome and COFCO Corporation Limited (“COFCO”) held a strategic cooperation agreement signing ceremony, announcing the establishment of a long-term partnership. The collaboration will strengthen cooperation across the supply of quality food products, brand and marketing initiatives, supply chain operations and elevating the overall customer consumption experience.

Curtis Liu, Chief Executive Officer, Food at DFI Retail Group (back row, fifth from left) and Mr. Lijun Qing, Vice President at COFCO Corporation Limited (back row, third from right) attended the signing ceremony with their teams to announce the strategic partnership
Curtis Liu, Chief Executive Officer, Food at DFI Retail Group (back row, fifth from left) and Mr. Lijun Qing, Vice President at COFCO Corporation Limited (back row, third from right) attended the signing ceremony with their teams to announce the strategic partnership

COFCO is an international agribusiness with a fully integrated food supply chain, underpinned by strong upstream sourcing capabilities and extensive supply chain management expertise. Wellcome is Hong Kong’s leading supermarket chain with the city’s largest store network. By leveraging their complementary strengths, the partnership aims to further enhance the supply of quality food products and offer customers a wider selection of fresh, great‑value choices.

Looking ahead, the two parties will focus on collaboration across four key areas:

  • First, strengthening the direct supply of quality products, with a diverse range of premium food products under COFCO prioritised for listing across Wellcome’s sales channels. This will expand offerings in key categories such as rice, flour, edible oils, dairy products, meat, alcoholic beverages, tea and beverages.
  • Second, enhancing supply chain efficiency by leveraging Wellcome’s local delivery and store network to accelerate the flow of fresh and fast‑moving consumer goods.
  • Third, driving joint brand and marketing initiatives, including new product launches, festive promotions and campaigns promoting healthy eating.
  • Fourth, strengthening food quality and safety management by strictly adhering to food safety standards and enhancing product traceability mechanisms, jointly safeguarding customers’ food safety.

At present, the key areas of cooperation include Mengniu dairy products, Fortune edible oil, Meilin canned food, and Joycome meat. In 2026, sales of COFCO’s products at Wellcome are expected to exceed HK$100 million. COFCO will prioritise supplying Wellcome with a broader range of quality products, while Wellcome will leverage its extensive local retail network to support COFCO with a stable and scalable sales channel in Hong Kong.

Through this partnership, both parties aim to provide customers with greater peace of mind and a wider range of quality food products, responding to Hong Kong families’ growing demand for better living. The first phase of the partnership’s promotional rollout features Joycome chilled pork, delivered fresh daily and offered at a long‑term promotional price of HK$28. Available from today at all Wellcome stores, the product is sourced directly from its origin, enabling Wellcome to offer customers produce of the highest quality.

Curtis Liu, Chief Executive Officer, Food, at DFI Retail Group, said: “This partnership between Wellcome and COFCO brings together the complementary strengths of both parties — COFCO’s robust food supply chain and Wellcome’s strong online and offline retail network. By combining these capabilities, we can further strengthen the stable supply of quality food products and offer customers a broader range of fresh products at great value.”

COFCO (Hong Kong) Limited’s spokesperson said: “The establishment of this long‑term strategic partnership with Wellcome fully leverages COFCO’s strengths in food supply chain capabilities and product resources, together with Wellcome’s territory‑wide retail network, enabling a wider range of quality food products to be supplied to the Hong Kong market more efficiently. COFCO will continue to provide Wellcome with a diverse and high‑quality product offering, working together to meet local households’ needs for food quality and supply stability.”

Hashtag: #WellcomeHK #COFCO




The issuer is solely responsible for the content of this announcement.

Wellcome

Established in 1945, Wellcome is Hong Kong’s longest established supermarket chain with the largest store network. Since 1964, the company has been wholly owned by DFI Retail Group and serves as the Group’s key supermarket brand in its food business. Together with Market Place, 3hreesixty and Oliver’s, Wellcome operates a network of over 320 stores serving more than 14 million customers every month.

With the mission of ‘Always Fresh, Always Value and Always Here for You’, we take pride and passion in providing a quality range of fresh and grocery products, great value and an exciting shopping experience to help our customers save more and enjoy more. As a market-leading supermarket, Wellcome constantly innovates to serve our communities better. In 2021, it introduced a new format, Wellcome Fresh, which offers great value and high-quality fresh produce in an environment that combines the atmosphere of a wet market with the convenience of a supermarket. In 2025, Wellcome launched “Everyday Value” price commitment, locking prices on over 400 fresh & grocery essentials for customers. More recently, it has accelerated its e-Commerce development, enhancing the omnichannel customer journey by offering a more convenient, flexible and personalised grocery shopping experience. For more information about Wellcome, please visit http://www.wellcome.com.hk.

COFCO Corporation Limited

COFCO Corporation Limited, founded in 1949, is a major international agri-food enterprise with a global presence and an integrated value chain spanning the entire agricultural and food industry. In 2025, it ranked 133rd on the Fortune Global 500 list. At present, the COFCO’s annual revenue exceeds 600 billion RMB, and it ranks first nationwide in both the scale and volume of trading, processing, and manufacturing of major agricultural products. Its brands, including Fortune, Mengniu, Great Wall, China Tea, Joycome, Meilin, Jiugui, Lohas, and Xiangxue, are widely recognized and well regarded.

As a central state-owned enterprise that shares the same founding year as the People’s Republic of China, COFCO has enjoyed a deep and longstanding bond with Hong Kong over several decades. Since the 1960s, under the unified arrangements of the state, COFCO has borne full responsibility for organizing and securing the supply of fresh food as well as grain and oil products for Hong Kong through the “Three Express Trains” from the mainland. From the departure of the first train in 1962 to the retirement of the “Three Express Trains” in 2010, COFCO continuously overcame various difficulties to ensure a steady flow of fresh food, fruits, and vegetables from the mainland to Hong Kong, day in and day out. The “Three Express Trains” functioned like three major arteries, delivering a constant supply of fresh produce from the mainland to Hong Kong and Macao, which not only enriched the year‑round food baskets of local residents but also provided solid support for the economic development and social stability of both regions.

TPIsoftware Announced Collaboration with Phison Electronics to Establish AISO for Accelerated On-Premises AI Implementation

TAIPEI, March 26, 2026 /PRNewswire/ — TPIsoftware (TPEx: 7781) announced a strategic collaboration with Phison Electronics to establish AISO, an alliance whose mission is to empower nations to build their own AI with market-proven, credible solutions. AISO, which stands for AI for Sovereignty, includes industry leaders: Gogolook, KDAN, TNP, TSTI, Altos, Thinktron, FUCO & Ryzo, Acer Synergy Tech, ECS and Fongcon as founding members, with guidance by Taiwan’s Industrial Technology Research Institute (ITRI).

The AISO launch was initiated by Phison CEO Pua Khein-Seng, Senior Executive Officer of the Ministry of Digital Affairs Hsu Mei-Ling, Counselor of National Development Council Lin Ching-Chin and TPIsoftware Chairman Ben Yao along with alliance members.
The AISO launch was initiated by Phison CEO Pua Khein-Seng, Senior Executive Officer of the Ministry of Digital Affairs Hsu Mei-Ling, Counselor of National Development Council Lin Ching-Chin and TPIsoftware Chairman Ben Yao along with alliance members.

The announcement took place at a press conference held on March 23. The event was followed by an MOU signing with Cathay Financial Holdings and Delta Electronics to solidify partnership, witnessed by representatives from the Ministry of Digital Affairs and National Development Council.

AISO is formed to enable turnkey delivery that accelerates AI deployment and adoption at the organizational level with integrated hardware-and-software solutions. This allied approach provides enterprises with affordability, scalability and reduced technical complexity of building on-premises AI. AISO focuses on developing a network with an AISO Inside standard that strengthens compliance with global legal frameworks, e.g. the EU AI Act, and national regulations while supporting the complete AI lifecycle.

TPIsoftware Chairman Ben Yao said that despite an abundance of AI solutions, the real challenge of AI adoption lies in the implementation process. The key is whether the AI capabilities are leveraged to create tangible value with proper data governance and regulatory compliance. The alliance aims to support AI deployment in highly-regulated industries including financial services, healthcare, public sector, etc., with bundled solutions for accelerated innovation and streamlined implementation at a fraction of the cost.

Phison CEO Pua Khein-Seng stated that with the company’s patented aiDAPTIV technology for enhanced inference, enterprises are able to bring AI into production at speed and scale with enterprise-ready software and affordable infrastructure by being part of the AISO network.

Cathay Financial Holdings CTO Marcus Yao highlighted that AISO enables on-premises architectures with enhanced governance and data residency, complementing their cloud-first strategy. Delta Electronics CIO/CISO L.F. Tseng added that the integrated solution provided by Phison and TPIsoftware ensures greater autonomy, compatibility and processing performance, driving AI transformation.

InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit


BEIJING, CHINA – EQS Newswire – 26 March 2025 – InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual results for 2025 as of December 13, 2025.

2025 marked InnoCare’s 10th anniversary and a milestone year of transformative growth and strategic execution. The Company achieved its first full year profitability, secured two new drug application (NDA) approvals, enhanced market penetration of its core products, accelerated globalization, and made breakthroughs across multiple pipelines. With numerous “China First” achievements, InnoCare continues to accelerate its 2.0 development strategy, demonstrating its strong ability to translate scientific innovations into sustainable long-term growth.

Financial Highlights

  • Revenue grew 135.3% year-on-year to RMB 2,375 million[1] in 2025, mainly driven by robust commercial growth and two strategic business development (BD) deals.
  • Profit reached RMB 644 million, achieving profitability for the first time, mainly due to significant commercialization growth and global out-licensing deals.
  • Gross Profit Margin increased by 5.7 percentage points to 92%.
  • Research and Development Investment increased by 16.9% to RMB 952 million in 2025, reflecting advancements of multiple Phase III registrational trials, as well as increased investments in new technology platforms such as ADCs and molecular glue.
  • Cash and Related Accounts Balance[2] stood at approximately RMB 7.8 billion as of December 31, 2025 and achieved positive operating cash flow for the first time. This strong cash position provides InnoCare with the flexibility to expedite global clinical development of key assets and invest in new technology platforms.

Accelerating Globalization with Transformative Deals

In 2025, InnoCare accelerated the implementation of its globalization strategy, unlocking global value of its core pipeline with two out-licensing deals, further enhancing the Company’s global influence and financial performance, and marking a significant step forward in its global expansion.

On Oct. 8, InnoCare entered into a transformative licensing agreement with Zenas for its autoimmune disease pipeline, including orelabrutinib. The agreement includes up to US$100 million in upfront and near-term milestone payments, and up to 7,000,000 shares of Zenas common stock, with a total deal value exceeding US$ 2 billion, setting a new record for small molecule autoimmune out-licensing in China.

This strategic collaboration marks a significant milestone in InnoCare’s globalization journey and will leverage shared focus to accelerate the global Phase III clinical development of orelabrutinib for the treatment of primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS), maximizing its clinical and commercial value worldwide, and advance a novel oral IL-17 AA/AF inhibitor and a brain-penetrant oral TYK2 inhibitor into clinical trials.

In addition, InnoCare entered into a licensing agreement with Prolium to further its global presence in 2025. In March 2026, Prolium announced first dosing of healthy volunteers in an ongoing single ascending dose study of ICP-B02 (PRO-203) and expects to initiate a multinational Phase I/II study of ICP-B02 in systemic sclerosis (SSc) in the second quarter of 2026, with additional studies in B-cell-driven autoimmune disease expected to follow.

Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, “Building on an inspiring decade of solid growth, we have continuously enhanced our fully integrated platform ranging from original innovation, clinical development, commercialization, manufacturing, to business development, achieving our strategic goal of break-even ahead of schedule, marking a significant milestone in our development history. As we enter our 2.0 phase of rapid development, we are focused on key strategic priorities, including securing approvals for five to six innovative drugs, advancing three to four products globally, and progressing five to ten differentiated molecules into clinical trials. We will further accelerate globalization, significantly increase revenue, and deliver more high-quality innovative therapies to benefit patients worldwide. ”

Building A Leading Franchise in Hemato-Oncology

In 2025, InnoCare made significant progress toward building a leading hemato-oncology franchise, driven by advances in commercial execution, late-stage clinical development, and global expansion.

InnoCare continued to strengthen its commercial portfolio with orelabrutinib approved for first line chronic lymphocytic leukemia/small lymphocytic lymphoma (1L CLL/SLL) and successfully included in the updated National Reimbursement Drug List (NRDL), while tafasitamab became the first CD19 antibody approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in China. As a result, drug sales increased by 43.4% to RMB 1,442 million in 2025.

Mesutoclax (ICP-248), the first BCL2 inhibitor granted Breakthrough Therapy Designation in China, continues to advance across multiple indications, including CLL/SLL, mantle cell lymphoma (MCL), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS), with clinical trials ongoing in China and globally. Together, these three assets form the core of InnoCare’s hemato-oncology strategy, supporting near-term revenue growth with a pipeline of differentiated, late-stage therapies.

Orelabrutinib

Orelabrutinib serves as a backbone therapy in InnoCare’s extensive hemato-oncology pipeline. Its newly approved 1L CLL/SLL indication has been included in the NRDL and is recommended as a Class I treatment in the Chinese Society of Clinical Oncology (CSCO) Diagnosis and Treatment Guidelines for Malignant Lymphoma. With all four approved indications now covered under the NRDL, orelabrutinib offers stable annual treatment costs, benefiting more lymphoma patients.

The commercial team further strengthened execution capabilities and sharpened strategic focus, delivering strong sales performance throughout 2025. Improved market penetration and operational discipline laid a solid foundation for sustained revenue growth and long-term commercial success.

Internationally, orelabrutinib continued to expand its regulatory footprint, with approval granted for relapsed or refractory marginal zone lymphoma (R/R MZL) in Singapore and NDA submission for R/R MCL successfully completed in Australia.

Tafasitamab

In May 2025, the tafasitamab regimen received NDA approval for adult patients with R/R DLBCL, representing the first CD19 antibody therapy approved in China for this indication and a key addition to InnoCare’s commercial portfolio.

Building on the initial commercial launch in September 2025, 2026 will mark the first full year of tafasitamab sales in China. Moreover, tafasitamab has been included as a Class II recommendation in the CSCO Guidelines, which will help address unmet clinical needs in this patient population and provide meaningful benefits.

Mesutoclax (ICP-248)

As the first BCL2 inhibitor granted BTD in China, mesutoclax has rapidly advanced across multiple registrational studies. The Phase III combination regimen with orelabrutinib for 1L CLL/SLL completed patient enrollment within 10 months, demonstrating strong clinical execution. This fixed-duration combination regimen has the potential to deliver deeper remissions, bringing hope for clinical cure and representing a promising treatment option.

A registrational trial in BTK inhibitor-treated MCL is progressing rapidly, and a Phase III randomized, double-blind, multicenter study of mesutoclax in combination with orelabrutinib versus pirtobrutinib (a reversible BTK inhibitor) in r/r MCL is expected to commence in 2026.

Global development of mesutoclax in AML and MDS is progressing across China, U.S., and Australia. The global AML and MDS markets are projected to reach US$8 billion[3] and US$11 billion[4] by 2034 respectively.

Mesutoclax, as a monotherapy or in combination with orelabrutinib, demonstrated a favorable safety profile for CLL/SLL across all dose levels tested. In the CLL/SLL patients receiving mesutoclax in combination with orelabrutinib, the overall response rate (ORR) was 100%, the complete response rate (CRR) was 57.1%, and the peripheral blood uMRD rate at 36-week was 65%. The clinical data from mesutoclax monotherapy demonstrated potential best in class efficacy in MCL patients, particularly in heavily treated patients with BTK inhibitor refractory. Among MCL patients who were BTK inhibitor-refractory, the ORR was 84.0% and the CRR was 36.0%. Mesutoclax in combination with orelabrutinib demonstrated a consistently favorable safety profile across B-cell malignancies (MCL, MZL, CLL/SLL). This oral, chemo-free regimen has the potential to establish a novel therapeutic option for B-NHLs. Updated data will be presented at 2026 American Society of Clinical Oncology (ASCO) annual meeting.

The combination of mesutoclax and azacitidine demonstrated a favorable safety profile and encouraging anti-tumor activity not only in AML but also in MDS patients. Among 35 evaluable treatment-naive AML patients, the regimen achieved an 85.7% composite CR rate and an 86.7% uMRD rate, with no mortality observed with 90 days. Preliminary data among MDS patients is also promising. There were no dose-limiting toxicities (DLT) or tumor lysis syndrome (TLS) events. Detailed data to be presented at 2026 ASCO annual meeting.

Developing B-cell and T-cell Pathways in Autoimmune Diseases

Autoimmune diseases can affect almost every organ in the body and may arise at any stage of life. The global market for autoimmune disease therapeutics is anticipated to reach $185 billion by 2029[5]. The Company has fortified its powerful discovery engine on cutting-edge global targets for the development of autoimmune therapeutics through B-cell and T-cell pathways, with the aim of delivering first-in-class and/or best-in-class treatments to address the massive unmet clinical needs and strong market potential in China and globally.

Orelabrutinib

Immune Thrombocytopenia (ITP): With over 200,000 new cases globally each year, including 60,000 in China, ITP represents a significant unmet medical need. The pivotal Phase III study has been completed, and the Company expects to submit the NDA application in the first half of 2026. ITP represents an important expansion of orelabrutinib from hematologic malignancies into autoimmune hematologic diseases, unlocking its enormous commercial potential. By leveraging the BTK inhibitor’s advantage in ITP, such as decreased macrophage-mediate platelet destruction and reduced production of pathogenic autoantibodies, orelabrutinib is well positioned to become a preferred BTK inhibitor in the field of ITP.

Systemic lupus erythematosus (SLE): There are about 8 million SLE patients worldwide. Orelabrutinib is the first BTK inhibitor to demonstrate significant efficacy in a Phase II clinical trial for SLE. The Phase IIb study met its primary endpoint, and a Phase III registrational study was initiated in the first quarter of 2026. Under stringent steroid-tapering requirements, orelabrutinib 75 mg once daily (QD) achieved a statistically significant improvement in SLE Response Index-4 (SRI-4) rate compared with placebo at Week 48 (57.1% vs. 34.4%, p < 0.05), meeting the primary endpoint. In a higher disease activity subgroup (BILAG ≥1A or ≥2B; SLEDAI-2K score ≥4), the 75 mg QD group achieved SRI-4 response rate of 68%, representing a 43% absolute improvement over placebo. Notably, 71.1% of patients in the 75 mg group achieving steroid reduction to ≤7.5 mg, compared with 43.6% in the placebo group. Multiple Sclerosis (MS): The US SPMS and PPMS market exceeds US$12 billion[6], representing a significant commercial opportunity. Based on the deal, InnoCare has been cooperating with Zenas to accelerate two global Phase III clinical trials of orelabrutinib for the treatment of PPMS and SPMS, further unleashing its global value in autoimmune diseases.

  • Initiated Orelabrutinib PriMroSe PPMS trial, a Phase III, global registration-directed, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of orelabrutinib in patients with PPMS in the third quarter of 2025. More information on the Phase III PriMroSe trial (NCT07067463) is available at clinicaltrials.gov.
  • Orelabrutinib Monarch trial for non-active SPMS (naSPMS) is planned, a Phase III, global registration-directed, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of orelabrutinib in patients with naSPMS is expected to initiate in the first quarter of 2026. More information on the Phase III Monarch trial (NCT07299019) is available at clinicaltrials.gov.

Two TYK2 Inhibitors

The global dermatology drug market has enormous potential, with over 500 million patients suffering from dermatological diseases worldwide. By 2035, the global dermatology market size is projected to reach nearly US$100 billion. InnoCare is well positioned to capture this opportunity with two TYK2 inhibitors targeting multiple high-value indications, including atopic dermatitis (AD), psoriasis, vitiligo, nodular prurigo (PN), urticaria (CSU), cutaneous lupus erythematosus (CLE), and other dermatological diseases. The global AD market is projected to reach $30 billion[7] by 2030, the vitiligo market $3 billion[8] by 2032, the CSU market $3 billion[9] by 2029, the psoriasis market $58 billion[10] by 2032, the PN market $3 billion[11] by 2034, and CLE market US$ 7.9 billion[12] by 2032.

Soficitinib (ICP-332)

The Phase III clinical study of soficitinib in patients with moderate to severe atopic dermatitis (AD) completed patient enrollment, with data readout expected in mid-2026. The Phase II clinical study of soficitinib in patients with vitiligo has also completed patient enrollment. Additional studies in prurigo nodular, urticaria, and psoriasis are progressing rapidly. As a result, soficitinib is expected to deliver a series of clinically meaningful data catalysts in 2026.

Data from the Phase II clinical trial of soficitinib in patients with moderate-to-severe AD were published in JAMA Dermatology in January 2026. The journal concluded that soficitinib demonstrated a favorable safety profile and encouraging efficacy in patients with AD.

Soficitinib achieved multiple efficacy endpoints in the study. The percentage improvement from baseline in EASI at Week 4 were 78.2% in the soficitinib 80 mg group, 72.5% in the soficitinib 120 mg group, and 16.7% for those receiving placebo. There was a statistically significant higher EASI-75 response rate with both soficitinib doses (64.0% for each; difference vs placebo, 56.0%) than with placebo and a greater percentage of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA) score of 0 or 1 and improvement of 2 or more points at Week 4 in the soficitinib 80 mg group vs placebo (36.0%; difference vs placebo, 32.0%, P=0.005). Meanwhile, soficitinib demonstrated rapid relief of pruritus and significant improvement in quality of life. Substantial reductions in Pruritus NRS severity and frequency scores were observed on Day 2 of treatment compared to placebo, with continued improvement over time, peaking at Week 4 for both severity and frequency (all P<0.05). ICP-488

The Phase III clinical study in psoriasis has completed patient enrollment, and the Phase II trial for CLE is progressing rapidly. The IND for Sjögren’s syndrome has been submitted, and additional indications and combination strategies are under evaluation.

Data on ICP-488 for the treatment of patients with moderate-to-severe plaque psoriasis has been released at the 2025 AAD Annual Meeting as a late-breaking oral presentation. The study results demonstrated that ICP-488 is highly effective in treating psoriasis at both the 6 mg QD and 9 mg QD doses. Moreover, ICP-488 exhibited favorable safety and tolerability profiles, reinforcing its potential as a valuable treatment option for moderate-to-severe psoriasis patients.

At week 12, the percentage of patients achieving PASI 75 was significantly superior in the ICP-488 6 mg QD group (77.3%) and the 9 mg QD group (78.6%) than that of the placebo group (11.6%); the percentages of subjects achieving PASI 90 and sPGA of 0 (clear) or 1 (almost clear) were also significantly higher in the ICP-488 6 mg QD group (36.4%, 70.5%) and 9 mg QD group (50.0%, 71.4%) compared to the placebo group (0%, 9.3%).

ICP-538

The first healthy volunteer has been dosed in a clinical trial of ICP-538, a VAV1-directed molecular glue degrader (MGD), in China. This is the first VAV1 degrader approved to enter clinical trials in China. ICP-538 is a novel, potent, highly selective, orally administered molecular glue degrader targeting VAV1, a key protein downstream of T-cell and B-cell receptors. ICP-538 induces rapid and efficient degradation of the VAV1 protein in a dose-dependent manner by selectively mediating the formation of a ternary complex between the CRBN E3 ubiquitin ligase and the VAV1 protein. ICP-538 will be developed for the treatment of autoimmune diseases, such as inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis. Currently, there are no approved VAV1-targeted therapies globally.

ICP-054

The IND application of ICP-054 (ZB021), a novel oral IL-17AA/AF inhibitor, was submitted. ICP-054 is a novel, oral, highly potent and selective IL-17AA/AF inhibitor with significant therapeutic potential in autoimmune and inflammatory diseases. ICP-054 can effectively block the signal transduction pathways of IL-17AA homodimer and IL-17AF heterodimer, thereby inhibiting the release of pro-inflammatory cytokines and chemokines, exerting an anti-inflammatory effect. Simultaneously, it reduces excessive proliferation of keratinocytes and inflammatory cell infiltration, improving skin lesions and thus suppressing the occurrence of autoimmune and inflammatory diseases.

Under the BD agreement, Zenas holds exclusive rights to develop, manufacture and commercialize the oral, IL-17AA/AF inhibitor in all territories outside Greater China and Southeast Asia.

Building Innovative Solid Tumor Assets

InnoCare has been building a robust and diversified portfolio to address significant unmet medical needs across multiple tumor types. The Company is committed to combining targeted small molecules with next-generation antibody-drug conjugates (ADCs) to maximize clinical benefit while minimizing systemic toxicity. The R&D team aims to focus on tumor types with high unmet needs, and to develop therapies that are differentiated in mechanism of action, potency, and safety profile. InnoCare’s proprietary ADC technology platform, alongside promising precision medicine candidates like zurletrectinib, positions the Company to establish a strong presence in the field of solid tumor treatment.

Zurletrectinib (ICP-723)

Zurletrectinib, a next generation TRK inhibitor, represents InnoCare’s first approved therapy in solid tumors and its third innovative product approved for marketing. Zurletrectinib is indicated for adult and adolescent patients (12–18 years) with NTRK gene fusion-positive tumors.

In the registrational clinical trial for patients with NTRK fusion-positive solid tumors, zurletrectinib demonstrated outstanding efficacy and a favorable safety profile. The study results showed an ORR of 89.1%, a disease control rate (DCR) of 96.4%, and 24-month progression-free survival (PFS) and overall survival (OS) rates of 77.4% and 90.8% respectively.

InnoCare expects to submit NDA for pediatric patients (2 years < 12 years) in the second quarter of 2026. In-House Developed Antibody-Drug Conjugate (ADC) Platform

The Company has developed a cutting-edge ADC platform with proprietary linker-payload (LP) technologies, aimed at the delivery of potent and targeted therapies for cancer treatment. This platform allows for the creation of highly differentiated ADCs with improved efficacy and safety profiles. Key features of the platform include:

  • Irreversible bioconjugation: ensuring stable antibody-linker bioconjugation for improved stability.
  • Hydrophilic linker: enhancing ADC stability and achieving a high drug-to-antibody ratio (DAR) of 8.
  • Novel payload: incorporating highly potent cytotoxic payloads with a strong bystander killing effect.

The platform is expected to deliver ADCs with strong tumor-killing efficacy and an adequate therapeutic window, thereby broadening treatment options for cancer patients and improving their clinical outcomes. As the platform continues to evolve, the Company is poised to expand its portfolio with multiple differentiated ADC candidates, further advancing precision medicine in oncology.

ICP-B794: A Novel B7-H3 Targeted ADC for Solid Tumors

InnoCare is advancing the Phase I dose escalation trial of novel B7-H3 targeted ADC, ICP-B794. ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to a potent in-house developed payload via a protease-cleavable linker. This combination ensures precise targeting of tumor cells while minimizing off-target effects, offering a promising treatment for solid tumors such as lung cancer, esophageal cancer, nasopharyngeal cancer, head and neck squamous cell carcinomas, prostate cancer, and others. ICP-B794 has demonstrated superior anti-tumor activity in animal models compared with other ADCs, and exhibited significant tumor-killing effects even in large tumors.

Early clinical observations indicate favorable pharmacokinetics and tolerability, with preliminary signs of antitumor activity, which validate the Company’s proprietary ADC platform for solid tumor development.

ICP-B208: A Novel CDH17 Targeted ADC for Solid Tumors

Building on the encouraging efficacy and safety of ICP-B794, the second ADC candidate, ICP-B208, is designed to target CDH17, a calcium-dependent cell adhesion protein that plays a key role in tumor cell proliferation, migration, and metastasis. Its tumor-restricted expression and functional role in cancer biology make CDH17 an attractive and differentiated target for ADC therapy, enabling the delivery of potent cytotoxic payloads specifically to tumor cells while minimizing systemic toxicity, which can be developed for the treatment of gastrointestinal cancers, including gastric, colorectal, pancreatic ductal adenocarcinoma, and cholangiocarcinoma. Preclinical studies show that ICP-B208 demonstrates good anti-tumor activity even in CDH17-low tumors. The IND application has been submitted in March 2026.

InnoCare plans to submit at least two more ADC INDs within 2026, further expanding its differentiated solid tumor pipeline.

To know more about the detailed financial data and business updates of InnoCare 2025 annual results, please log in to https://www.innocarepharma.com/en/investor/home .

Conference Call Information

InnoCare will host a conference call at 8:30 p.m. Beijing time on March 25 in English and at 9:00 a.m. Beijing time in Chinese on March 26, 2025. Participants must register in advance of the conference call. Details are as follows:

For English conference call, please register through the below link:
https://goldmansachs.zoom.us/webinar/register/WN_rVCbaOqMSM-QJQlfzlTEvw

For Chinese conference call, please register through the below link:
https://s.comein.cn/qz7duugd

Forward-looking Statement

This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management’s intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.


[1] The financial figures in this article are based on Hong Kong Financial Reporting Standards
[2] Include cash and bank balances, other current assets, financial assets among other non-current assets, and interest receivable
[3] Global Growth Insights
[4] Nova One Advisor, Insight Code: 8817
[5] iHealthcareAnalyst, Inc., Oct. 3, 2023
[6] Zenas estimate based on reported prevalence and current pricing of B cell therapies approved for MS
[7] Grand View Research
[8] Data Bridge Market Research
[9] The Business Research Company
[10] Fortune Business Insights
[11] Global Market Insights
[12] Data Bridge Market Research

Hashtag: #InnoCare

The issuer is solely responsible for the content of this announcement.

About InnoCare

InnoCare (HKEX: 09969; SSE: 688428) is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and United States.

“REALIVE” – A Special New Program by Yuzuru Hanyu and the ICE STORY Team! Miyagi performance to be broadcast as Special Viewing to movie theaters in Taiwan, Hong Kong, Macau and Singapore!

Yuzuru Hanyu “REALIVE” an ICE STORY project Special Viewing

SINGAPORE, March 26, 2026 /PRNewswire/ — Footage from “Yuzuru Hanyu ‘REALIVE’ an ICE STORY project,” held at Sekisui Heim Super Arena in Miyagi Prefecture on Sunday April 12, 2026, will be broadcasted at movie theaters as Special Viewing on Tuesday, April 14.

Yuzuru Hanyu “REALIVE” an ICE STORY project Special Viewing
Yuzuru Hanyu “REALIVE” an ICE STORY project Special Viewing

Since turning professional, Yuzuru Hanyu has continued his activities while working on and refining his own skating, making various stories and forms of expression through his ICE STORY project.

The first installment, “Yuzuru Hanyu ICE STORY 2023 ‘GIFT'” was held at an ice rink set up inside the massive Tokyo dome, a world first for figure skating.

The second installment, “Yuzuru Hanyu ICE STORY 2nd ‘RE_PRAY’ TOUR,” centered on the theme of being alive, the third installment, “Yuzuru Hanyu ICE STORY 3rd ‘Echoes of Life’ TOUR,” presented a story and programs centered on the question of what ‘life’ itself means.

Now the team behind ICE STORY, with stories by Yuzuru Hanyu that come together with skating, music, visuals and lighting, has launched a new event called REALIVE.

Through REALIVE, a one-day live performance will take the programs that Yuzuru Hanyu has created over the years and bring them back to life again as living works.

Enjoy on a big theater screen a special program in which the numerous events held by Yuzuru Hanyu are once again engraved on the ice showcasing his current talents.

Yuzuru Hanyu “REALIVE” an ICE STORY project Official Site:
https://realive-icestory.jp/ 

Information】

Title> 
Yuzuru Hanyu “REALIVE” an ICE STORY project Special Viewing

Time> 
Tuesday, April 14, 2026, start at 18:30 (GMT+8)
*This “Special Viewing” is a replay of the performance held on Sunday 12 April.

Venue> 

Taiwan
Vieshow Cinemas Taipei HsinYi
Vieshow Cinemas Banciao Mega City
Vieshow Cinemas Taichung Taroko Mall
Vieshow Cinemas Tainan FE21
Vieshow Cinemas Kaohsiung FE21

Hong Kong
MCL K11 Art House
MCL Festival Grand Cinema
MCL Movie Town

Macau
Emperor Cinemas Lisboeta Macau

Singapore
Golden Village Suntec City

Attention】


*This “Special Viewing” is a replay of the performance held on Sunday 12 April.
*This screening is designed to be enjoyed like a regular live performance. Please be aware that applause and other audience sounds may occur during the screening.
*Please note that because this is a live broadcast, video and audio may be affected due to the network conditions.
*It is strictly prohibited to record any audio/video/photo with camera, mobile phone or any other devices of the streaming screen. You may be subject to criminal penalties for uploading and sharing it online without permission. If such an act is found at the cinema, you will be asked to delete the recorded contents, and leave the cinema immediately after doing so. The ticket will not be refunded in this case.
*In the event of an earthquake or a disaster warning, the show may be suspended for safety reasons, regardless of the area where the customer is located or the area where the performance is hosted.


*Please note that the screening times listed by each cinema are subject to change. If the performance significantly exceeds the scheduled end time, the screening may be terminated before the show concludes.
*Please note that photography or filming may occur in the cinema for records of the event or for usage by the press. Such videos and photos may be used in various media.


*Please note that due to the cinema’s seating arrangements, seats for your group may not be located together.

*When using support goods (such as flags, glow sticks, or towels), please be considerate of other audience members and avoid obstructing their view. The use of items that block others’ sight is prohibited.
*Refrain from loud cheering or behavior that may disturb others.
*Please remain in your reserved seat during the performance.
*Additional rules may apply depending on the theater.

*Published details are subject to change without prior notice depending on circumstances.

Yuzuru Hanyu “REALIVE” an ICE STORY project Special Viewing
Information Website
https://liveviewing.jp/overseas/realive-icestory-overseas/
Organized by:tv asahi/CIC/teamSirius/khb
Distributed by:Live Viewing Japan Inc.

【Precautions when using images】

The image cannot be cropped or processed for use.

 

Royal Healthcare in Singapore provides NEC’s “FonesVisuas Test” for Disease Risk Prediction

TOKYO, March 26, 2026 /PRNewswire/ — NEC Corporation (NEC; TSE: 6701) announced that its FonesVisuas Test, an innovative blood test that predicts disease risk, is being offered by Royal Healthcare (*1), a Singapore-based medical institution and group company of Sojitz Corporation that combines the latest medical expertise with the art of hospitality.

Entrance of the Specialist Medical Centre
Entrance of the Specialist Medical Centre

According to the World Health Organization (WHO), the global rise in lifestyle-related diseases and dementia underscores the urgency for advanced predictive diagnostics (*2). Concurrently, the Organisation for Economic Co-operation and Development (OECD) iLibrary data has identified cancer and cardiovascular diseases as leading causes of mortality worldwide (*3), amplifying the urgency for proactive health management solutions.

Royal Healthcare is based in Singapore’s medical hub, Novena, providing personalized, high-quality health screening services alongside customized medical experiences that prioritize efficiency and convenience for both local and international patients.

Interior of the Specialist Medical Centre
Interior of the Specialist Medical Centre

The addition of the FonesVisuas Test represents a significant advancement by analyzing proteins that reflect dynamic physiological changes. From just a small blood sample, the test can predict risks of developing conditions such as dementia, heart attack, lung cancer, chronic kidney disease, and prostate cancer over the next several years.

Royal Healthcare combines its services with conventional health checkups to guide individuals who are not yet ill but also not in optimal health toward lifestyle improvements. This approach aims to prevent future illness and enhance people’s quality of life.

Looking ahead, NEC plans to expand provision of the FonesVisuas Test internationally, particularly in the APAC region, underscoring its commitment to advancing global healthcare standards.

Notes

(*1) https://royal-healthcare.com/
(*2) https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases; https://www.who.int/news-room/fact-sheets/detail/dementia
(*3) https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2023_7a7afb35-en

About NEC

The NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group’s approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society.

For more information, please visit https://www.nec.com, and follow us on Instagram, Facebook, YouTube, and LinkedIn.

Focus on upgrading industries and collaboration

BEIJING, March 26, 2026 /PRNewswire/ — This is a news report from China Daily: 

The Beijing-Tianjin-Hebei region has laid a foundation for coordinated innovation and is set to intensify efforts in the transformation of scientific and technological achievements, industrial upgrading and technology finance, a senior official said.

Jin Wei, vice-mayor of Beijing, highlighted that research collaboration across the region has grown stronger. A dedicated joint fund under the National Natural Science Foundation of China has been established. It supports 270 projects, fostering collaboration among more than 700 research teams, and incubating 179 hard-tech enterprises.

In terms of industrial collaboration, the Beijing-Tianjin-Hebei region has mapped out six key industry chains, including hydrogen energy and biomedicine, and jointly developed seven advanced manufacturing clusters, such as integrated circuits and artificial intelligence.

This Wednesday marks the opening of the 2026 Zhongguancun Forum Annual Conference. The five-day event lists deepening coordinated innovation in the region as one of its priorities, and will host the Beijing-Tianjin-Hebei coordinated innovation and high-quality development forum as a parallel session on Friday.

The parallel forum will consist of six sessions, including keynote speeches, announcements, and cooperation signing ceremonies. It aims to connect cutting-edge technologies and international resources, explore pathways and models for coordinated regional innovation, and build a platform for exchanges and cooperation among governments, enterprises, universities and research institutions.

“We are jointly enhancing the prestigious reputation of Zhongguancun,” Jin said, adding that four such parks have been established in areas such as the Binhai New District in Tianjin and Xiong’an New Area in Hebei.

Beijing, Tianjin and Hebei have jointly set up operation teams, implemented supporting policies and improved cultivation systems. More than 9,800 enterprises have settled in these four parks. Notably, the park in Xiong’an New Area, inaugurated just over two years ago, has attracted more than 260 tech enterprises.

Looking ahead, Jin emphasized that the Beijing-Tianjin-Hebei region will continue to promote the transformation of sci-tech achievements and establish a regular mechanism for aligning research outcomes with practical applications.

The region will also organize strategic sci-tech forces, such as national laboratories, universities and research institutes, to cooperate with key enterprises in Tianjin and Hebei, and build industrialization carriers in areas such as Tongzhou, Wuqing and Langfang.

A staff member of Tianjin Siasun Intelligent Technology operates a mine inspection robot in the Beijing-Tianjin Zhongguancun Tech Town in Tianjin.
A staff member of Tianjin Siasun Intelligent Technology operates a mine inspection robot in the Beijing-Tianjin Zhongguancun Tech Town in Tianjin.

Forrester: Asia Pacific Tech Spending Expected To Grow 9.3% In 2026, But Rising Costs And Regulations Will Impact Real Growth

Escalating tech costs, volatile hardware markets, energy supply disruptions, and sovereignty mandates will erode purchasing power in the region

SINGAPORE, March 26, 2026 /PRNewswire/ — According to Forrester’s (Nasdaq: FORR) Asia Pacific Tech Market Forecast, 2026 To 2030, the region will spend over US$437 billion on acquiring new technology between 2025 and 2030. Forrester estimates that total spending on technology will grow by 9.3%, driven by investments in software, services, communications equipment, and tech outsourcing, but cost pressures (such as software inflation and hardware spikes), regulatory fragmentation, tariffs, energy shocks, uneven regional growth, and talent shortages will reduce the real impact of that investment.

Across Asia Pacific, computer equipment will see the strongest growth at 13.7%, boosted by hyperscalers’ investments in AI-optimized data centers and higher hardware prices tied to global component shortages. Software spending will grow 10.7%, with adoption of agentic AI accelerating and vendors incorporating AI-enhanced capabilities into renewal pricing.

In 2026, Forrester projects tech spend growth across countries in the Asia Pacific to be:

  • 8.6% in Australia. Australia’s tech spending is forecast to reach nearly A$110 billion (US$70.6 million) in 2026, outpacing the country’s projected 2.2% GDP growth. Software prices are rising at nearly five times general inflation as vendors embed AI capabilities into contract renewals.
  • 10.7% in China. China’s AI infrastructure spending will exceed US$70 billion in 2026, fueled by major investments from Alibaba and ByteDance as well as the Ministry of Industry and Information Technology’s industrial digitalization mandate. Data center and cloud platform buildout remain strong, but weak domestic demand and deflationary pressures will slow traditional enterprise IT spending.
  • 13.4% in India. As Asia Pacific’s fastest-growing market, India is being propelled by rapid cloud adoption and data localization rules that are driving major onshore infrastructure investment. Software investment is also rising as vendors embed AI capabilities into renewal pricing, while domestic enterprise demand continues to be the primary driver of India’s double-digit tech spending growth.
  • 6% in Singapore. Singapore’s growth is anchored to strong investment in AI transformation and hyperscaler expansion, but a significant talent shortage remains the main constraint on technology adoption as many employers continue to lag in developing their AI workforce.
  • Strong in Southeast Asia. In 2026, tech spending will grow across Southeast Asia: 12.5% in Indonesia, 9.5% in Malaysia, 12.3% in the Philippines, 6.8% in Thailand, and 15.4% in Vietnam. The region’s digital economy has shifted from user acquisition to monetization, with digital services income reaching US$11 billion in 2024 — 2.5x higher than in 2022. Cross-border QR payment interoperability is accelerating financial digitization, while Industry 4.0 adoption continues to scale across Indonesia, Vietnam, and Thailand.

“Asia Pacific’s technology spending momentum remains strong, but the headline growth numbers mask a more complex reality,” said Frederic Giron, VP and senior research director at Forrester. “CIOs across the region are grappling with software inflation, hardware volatility, and increasing regulatory divergence that directly impact modernization plans. The conflict in the Middle East adds a new macro headwind — sustained energy cost inflation will compress GDP growth across oil-dependent countries in Asia. The CIOs in those markets should expect IT budgets to come under pressure if the conflict lengthens. To navigate this environment, leaders must shift to highly targeted investments — prioritizing automation, AI-enhanced platforms, and modernization initiatives that deliver measurable productivity gains.”

Resources:

  • Read about Forrester’s Asia Pacific Tech Market Forecast, 2026 To 2030, in this blog or download the report here (client access required).
  • Download Forrester’s 2026 Predictions guide to explore the critical questions that tech and security leaders must answer in 2026.

About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We empower leaders in technology, customer experience, digital, marketing, revenue, and product functions to be bold at work and accelerate growth through customer obsession. Our unique research and continuous guidance model helps executives and their teams achieve their initiatives and outcomes faster and with confidence. To learn more, visit Forrester.com.